CD8A and neoplasm: Finally, the immunostimulatory activity of sLAG-3 in inducing tumour-associated human antigen-specific CD8+ T cell responses to a much greater extent than CpG ODN [9] has been reported recently [10], further supporting the use of this recombinant protein as a promising candidate adjuvant for cancer vaccination.